drugset / Trial / NCT01104675
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.
Timeline
- Start
- 2010-04
- Primary completion
- 2011-08
- Completion
- 2012-12
Outcome
Met primary endpoint
release “EntreMed's ENMD-2076 Demonstrates Promising Activity in a Phase 2 Study in Platinum-Resistant Ovarian Cancer Patients Primary Endpoint Data Show Clinical Benefit” issuerdirect.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ENMD-2076 | Small molecule | 250 mg | Oral |
| Subject | ENMD-2076 | Small molecule | 275 mg | Oral |